Skip to main content
    F

    Fortress Biotech Inc Pref Series A (FBIOP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.86
    -0.50 (-3.52%)

    Market Cap: $77.81M

    Last updated: Nov 17, 2026 at 10:47 AM ET

    Fortress Biotech Inc Pref Series A (FBIOP) Financials: Revenue, Profit and Cash Flow

    Updated Sep 30, 2026. Financial statements from company filings, amounts in US dollars.

    Fortress Biotech Inc Pref Series A reported revenue of $63.26M for the fiscal year ended Dec 31, 2025, up 9.7% from the year before. That year, net income was $6.82M with a net margin of 10.8%, operating cash flow was -$65.78M and free cash flow was -$65.78M. The quarter ended Sep 30, 2026 had revenue of $19.16M and net income of -$5.84M.

    Revenue and Margins

    The net margin was 10.8% in the fiscal year ended Dec 2025, the highest of the 5 years shown with a net margin. Over the 9 years to Dec 2025, revenue grew from $16.48M, a compound annual rate of 16.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$63.26M+9.7%66.9%-111.0%10.8%
    Dec 2024$57.67M-31.8%63.8%-191.4%-79.8%
    Dec 2023$84.51M+11.6%72.9%-168.4%-71.7%
    Dec 2022$75.74M+10.1%59.4%-268.8%-114.3%
    Dec 2021$68.79M+50.9%53.4%-274.1%-94.1%
    Dec 2020$45.60M+24.5%68.0%-206.7%-102.0%
    Dec 2019$36.63M+36.3%71.2%-302.5%-109.1%
    Dec 2018$26.88M-85.7%77.2%-446.4%-313.0%
    Dec 2017$187.58M+1038.3%14.1%-47.9%-35.7%
    Dec 2016$16.48MN/A31.1%-398.7%-334.3%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$63.26M$57.67M$84.51M$75.74M$68.79M$45.60M$36.63M$26.88M$187.58M$16.48M
    Cost of revenue$20.92M$20.88M$22.89M$30.77M$32.08M$14.59M$10.53M$6.13M$161.20M$11.35M
    Gross profit$42.34M$36.80M$61.62M$44.97M$36.71M$31.00M$26.10M$20.76M$26.38M$5.13M
    Research and development$11.90M$56.88M$106.07M$134.88M$128.87M$64.11M$81.33M$87.38M$52.49M$35.13M
    Operating income-$70.22M-$110.38M-$142.34M-$203.56M-$188.54M-$94.27M-$110.82M-$120.00M-$89.80M-$65.71M
    Net income$6.82M-$46.00M-$60.64M-$86.58M-$64.70M-$46.53M-$39.96M-$84.15M-$66.88M-$55.09M
    EBITDA-$20.16M-$104.49M-$135.72M-$193.69M-$146.17M-$87.82M-$88.48M-$118.40M-$88.57MN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$19.16M$18.72M$16.04M$16.08M$17.63M$16.41M$13.14M$15.12M$14.63M$14.90M$13.03M$19.95M
    Gross profit$13.28M$11.61M$8.69M$10.64M$11.88M$11.47M$8.35M$9.31M$9.34M$8.36M$7.03M$13.93M
    Operating income-$7.19M-$10.01M-$7.74M-$4.79M-$6.81M-$36.47M-$22.32M-$27.34M-$22.09M-$27.79M-$36.57M-$19.61M
    Net income-$5.84M-$468.00K$110.37M-$3.94M$5.85M$15.49M-$10.58M-$6.76M-$12.87M-$10.95M-$15.42M-$9.28M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $61.63M by $17.75M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$185.55M$144.22M$167.53M$294.30M$396.50M$333.41M$226.42M$140.99M$245.95M$170.73M
    Current assets$123.84M$90.37M$117.02M$230.43M$346.46M$266.15M$156.25M$111.21M$183.18M$109.63M
    Cash and equivalents$79.38M$57.26M$80.93M$178.27M$305.74M$233.35M$136.86M$65.51M$113.92M$88.29M
    Total liabilities$123.36M$145.87M$165.94M$244.28M$170.63M$136.41M$153.89M$121.25M$125.45M$87.76M
    Short-term debt$2.13M$3.25M$5.52M$12.63M$7.43M$6.37M$9.00M$19.08M$13.23M$2.03M
    Long-term debt$59.50M$57.96M$60.86M$93.14M$46.56M$59.04M$82.43M$60.42M$53.28M$26.18M
    Shareholder equity$49.87M$22.74M$22.54M$41.72M$108.67M$100.34M$26.21M$1.85M$52.57M$38.49M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$280.21M$316.71M$356.87M$185.55M$181.41M$159.90M$178.07M$144.22M$127.08M$145.69M$164.65M$167.53M
    Total liabilities$103.19M$110.63M$154.50M$123.36M$116.22M$122.51M$145.59M$145.87M$139.82M$160.28M$168.58M$165.94M
    Cash and equivalents$152.19M$196.58M$255.84M$79.38M$86.22M$74.39M$91.34M$57.26M$58.85M$76.20M$85.84M$80.93M
    Shareholder equity$160.00M$164.14M$162.21M$49.87M$55.86M$43.92M$22.25M$22.74M$21.16M$17.88M$23.02M$22.54M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$65.78M-$80.19M-$128.22M-$179.40M-$116.54M-$83.68M-$94.96M-$98.85M-$85.43M-$45.81M
    Capital expenditures$0$15.00M$8.10M$3.06M$16.35M$7.16M$9.39M$9.36M$5.45M$10.51M
    Free cash flow-$65.78M-$95.19M-$136.32M-$182.46M-$132.89M-$90.85M-$104.36M-$108.20M-$90.88M-$56.32M
    Dividends paid$664.00K$4.71M$8.77M$8.78M$8.78M$6.75M$2.56M$2.34M$299.00K$299.00K
    Investing cash flow$10.12M-$15.00M-$2.10M-$22.93M$40.51M-$7.16M$20.10M$18.82M-$41.63M-$6.06M
    Financing cash flow$77.44M$70.64M$32.74M$75.32M$148.99M$172.41M$146.71M$50.65M$150.38M$42.91M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$6.20M-$59.28M$203.85M-$12.54M-$6.11M-$27.56M-$19.56M-$12.91M-$20.06M-$21.84M-$25.39M-$34.94M
    Capital expenditures$7.00K$79.00K$0$0$0$0$0$0$0$0$0$63.00K
    Free cash flow-$6.20M-$59.36M$203.85M-$12.54M-$6.11M-$27.56M-$19.56M-$12.91M-$20.06M-$21.84M-$25.39M-$35.00M
    Last 12 quarters

    Frequently Asked Questions About FBIOP

    What is Fortress Biotech Inc Pref Series A's annual revenue?

    Fortress Biotech Inc Pref Series A reported revenue of $63.26M for the fiscal year ended Dec 31, 2025.

    How fast is Fortress Biotech Inc Pref Series A's revenue growing?

    Revenue was up 9.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -5.8%.

    Is Fortress Biotech Inc Pref Series A profitable?

    Yes. Fortress Biotech Inc Pref Series A reported net income of $6.82M for the fiscal year ended Dec 31, 2025, with a net margin of 10.8%.

    How much free cash flow does FBIOP generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$65.78M minus capital expenditures of $0 produced free cash flow of -$65.78M.

    How much debt does Fortress Biotech Inc Pref Series A have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $59.50M, short-term debt of $2.13M and cash and equivalents of $79.38M.